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1. Introduction
Of all cerebral strokes, hemorrhagic stroke forms approximately 15%, of which hypertensive 
intracranial hematomas (HIH) constitute the vast majority [1, 2]. Intracranial hemorrhage (ICH), 
contrary to popular belief, is not a ‘modern disease’ and is mentioned as ‘Cerebral Apoplexy’ in 
the writings of antiquity credited to Hippocrates [3]. ICH can be attributed to a number of under-
lying pathologies including amyloid angiopathy, cryptic vascular malformations, arteritis and 
hypertension [3]. Despite modern imaging such as computed tomography (CT) and magnetic 
resonance imaging (MRI), diagnostic uncertainty inhibits a serious study of the natural history 
and epidemiology of ICH [3]. ICH is predominantly of two types: primary ICH, when no under-
lying pathology is identifiable and secondary ICH, when hemorrhage occurs in a pre-existing 
lesion such as a tumor or arteriovenous malformation [2, 3].
ICH occurring spontaneously is often referred to as ‘Hypertensive’ in common medical par-
lance, and there is little doubt that elevated blood pressures promote the occurrence of ICH; 
although several environmental factors have been identified as risk factors, hypertension 
remains the single most relevant of them all [3]. A systematic review of literature has demon-
strated that hypertension is one of the commonest and most prevalent risk factors associated 
with ICH [1, 4]. A 3.5-fold increase in the incidence of ICH is noted in hypertensive patients in 
comparison with normotensive patients [2]. Isolated systolic hypertension is found to correlate 
most strongly with ICH in contrast to diastolic hypertension and borderline isolated systolic 
hypertension [1]. The other factors found to have some relevance to the occurrence of ICH are 
cigarette smoking(increases risk of ICH by 4x to 5x), alcohol consumption, diabetes mellitus, use 
of oral contraceptives and male gender [1, 3]. There has also been an association between low 
mean serum cholesterol and the incidence of ICH, especially in the older individuals [3, 5]. HIH 
also has a racial predilection, being highest in Asian population and least in the Caucasians [3]. 
Of the myriad diseases being studied today, HIH is not only one of the many which is being 
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investigated so thoroughly that a clear understanding of the risk factors and their modifications 
has attributed to the plunging incidence of the disease [3].
2. Clinical presentation
Clinical symptomatology of the ICH is dependent on the dissection of the brain tissue by the 
expanding hematoma and mass effect, implying the importance of the location and size of the 
hematoma [6]. Location of HIH is usually in the deep nuclei of the brain: basal ganglia (40%), 
the thalamus (10–25%), the cerebellum (5–10%) and the pons (5%) [6]. Thalamic hematomas 
may further be subdivided into four different locations: anterolateral (21%), medial (15%), 
posterolateral (55%) and dorsal (9%) [7]. Lobar hematomas involving the neocortex account 
for 20% or less [6]. The hallmark of ICH is ‘Acute neurological deficit with rapid progres-
sion,’ in contrast to ischemic strokes [6]. Fluctuating neurological symptoms are extremely 
uncommon [6]. The general symptoms include raised intracranial pressure which manifests 
as headache (33–57%), nausea and vomiting (29–46%) and decrease in the level of conscious-
ness (28–37%)] [6]. At presentation, 4–20% of ICH patients are in a coma [6]. Meningeal irrita-
tion manifesting as neck stiffness and seizures (<10%)] are other general symptoms of ICH [6]. 
Symptomatology related to the location of the hematoma varies. Cortical lobar hematomas in 
the dominant hemisphere can present with higher mental function symptoms such as apha-
sia, acalculia or motor apraxia [6]. Non-dominant hemispheric symptoms appear as left-side 
neglect, agnosia or visuospatial dysfunction [6]. Hematomas may present with symptomatol-
ogy specific to the cerebral lobe involved such as abulic-apathetic behaviors with frontal lobe 
involvement and contralateral homonymous hemianopsia with occipital lobe involvement 
[6]. The involvement of the deep grey nuclei usually depends on the location and direction 
of the hematoma expansion, e.g., caudate nuclei hematomas may involve the anterior limb of 
the internal capsule involving predominantly frontothalamic and frontopontine fibers mani-
festing as prominent neurobehavioral changes, in contrast to putaminal hematomas which 
usually involve the posterior limb of the internal capsule and may present with contralateral 
hemiparesis or hemiplegia [6]. Caudate and thalamic aphasias may occur in the dominant 
hemisphere [6]. Cerebellar hematomas may demonstrate the typical ‘Cerebellar Syndrome,’ 
and pontine hematomas may present with dense quadriplegia or the typical ‘locked-in syn-
drome’ in addition to cranial nerve deficits [6].
2.1. Expansion of ICH
Expansion of ICH appears to be more common than initially thought. Over a third of 
patients may demonstrate the expansion of hematoma over the first 24 h [6]. A fivefold 
morbidity has been reported with the expansion of the ICH and a significant cause of death 
in these patients [8]. The radiographic criteria for hematoma expansion have been reported 
as an increase in hematoma volume by ≥12.5 cm or by ≥1.4 times [8]. Temporally, the high-
est probability of hematoma expansion is seen in the hyperacute stage (17% within the first 
6 h) [8]. Hematoma enlargement after 24 h rarely occurs [8]. It stands to reason, therefore, 
Hemorrhagic Stroke - An Update2
if a hyperacute CT scans reveal an ICH, repeat scans should be considered periodically. 
There have been speculations about the etiology of the expansion, viz. whether there occur 
repeated small hemorrhages or there is a continuous oozing [9]. Expansion of an ICH gener-
ally follows the general ‘rule of thumb,’ and the larger the hematoma at presentation, the 
more likely it is to expand [10].
Interestingly, hematoma expansion has been shown to be an independent determinant of 
morbidity and mortality in ICH [11]. For an increase of 10% in the size of the ICH, there 
appears to be a 5% increased hazard of death [12].
3. Pathophysiology and etiopathogenesis of ICH
It has been proven that ICH usually occurs in the area supplied by small perforating arte-
rioles (50–700 μm in dia.) and the rupture occurs as a consequence of hypertension-related 
pathological changes which include fibrinoid necrosis, microaneurysm formation and lipo-
hyalinosis [6]. It is conjectural that the pulse pressure may in fact be more important than the 
absolute blood pressure, since the turbulence generated would damage the vessel resulting 
in a rupture if collagen is inadequate especially in the presence of repetitive cycles of arte-
riolar dilatation [7]. The Charcôt-Bouchard aneurysm, which has been a controversy since 
its original description, is a fusiform dilatation of the thinning, vasculopathic arteriolar wall 
which virtually entirely consists of collagen [7]. The controversy has stemmed from the use of 
the term ‘aneurysm’ for the ‘non-saccular,’ ‘fusiform’ dilatation of the vessel walls [7]. These, 
then, morphologically, characterize a segmental disease, fusiform (dilatation by a factor of 
two or three, over lengths of 100–200 μm), which has been revealed by the use of alkaline 
phosphatase techniques and may be visualized in the pathological specimen of the hematoma 
as extensions of a vessel into an acute hematoma lined by a endothelial lining [7].
4. Management
The management is symptomatic and mainly supportive, and no definite treatment modal-
ity has proven to improve outcomes in ICH [6]. Mortality is high, generally ranging from 
30 to 55% with a very high case fatality rate in the first 7 days [6]. The long-term prognosis 
for the survivors is not very encouraging with less than 30% of patients being independent 
at 3 months of the ICH ictus [6]. The goals of management therefore include prevention of 
further brain injury by deterring hematoma expansion, restricting edema and to attempt 
recruiting the brain’s plasticity to improve the rehabilitation outcome [9]. Prehospital 
management is vital and primarily consists of ventilator and cardiovascular support and 
transporting the patient to the nearest available stroke unit [9, 13]. Management at the emer-
gency room (ER) consists of a thorough neurological assessment, management of elevated 
blood pressures and neuroradiological evaluation and may entail emergency procedures 
such as insertion of an external ventricular drain, monitoring ICP and its management and 
reversal of coagulopathy [13]. Critical pathways should be formulated and followed at the 
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ER level [13]. Computed tomography and magnetic resonance imaging are both reasonable 
initial modalities of investigation, especially if the differentiation between infarction and 
hemorrhage is difficult clinically [13]. However, CT is considered the gold standard for the 
diagnosis of hemorrhage [13]. Intensive blood pressure lowering has been evaluated by 
several trials, and the majority of results reflect a proclivity toward rapid reduction to less 
than 140 mm Hg [10]. This seems clinically reasonable, generally well tolerated and appears 
to impact hematoma expansion in ICH [10].
4.1. Ultra-early hemostatic therapy for ICH
Ultra-early hemostatic therapy for ICH is recommended because an increase in the hematoma 
volume and expansion are associated with poorer outcome [12]. ICH has an increased inci-
dence in patients on oral anticoagulants or antiplatelet drugs and those with coagulation fac-
tor deficiencies and platelet abnormalities [12]. Ultra-early hemostatic therapy is particularly 
indicated in these patients and includes appropriate intervention, such as platelet transfu-
sions or administration of vitamin K, in addition to the other management options outlined 
above [12].
4.2. Surgical management
Early studies had failed to demonstrate any significant difference between conservative and 
surgical management of ICH [9]. There were also reports of poorer surgical outcome due to 
the trauma of surgery itself and a higher postoperative re-hemorrhage rate [7]. There have 
been over a dozen randomized controlled trials, addressing the issue of the surgical manage-
ment of ICH [9]. The surgical approach to the hematoma depends on the location and the 
depth of the hematoma and eloquence of the brain involved among other considerations [9]. 
It has also been reported that surgery may be beneficial only if undertaken within 8 h of ictus, 
thus limiting the toxic effects of the blood components on the brain [14].
4.3. Recent advances and trials
The initial Surgical Trial in ICH (STICH) trial of over 1000 patients did not reveal any statisti-
cally significant benefit of surgery for supratentorial ICH except for hemorrhage within 1 cm 
of cortical surface [7]. The STICH II trial for lobar hematomas found a small (3.7%) absolute 
benefit in the surgical group, but it was riddled with controversy because of the inclusion 
of patients with a normal level of consciousness (i.e., clinically no evidence of raised ICP) 
[14]. The STICH II trial, however, did demonstrate significant benefit from surgery in the 
group that was considered a poor prognosis group (i.e., low GCS and a large hematoma vol-
ume) [14]. There have been several recent trials researching minimally invasive surgical tech-
niques such as endoscopic or stereotactic aspiration with or without fibrinolytic agents [9]. 
‘Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation’ (MISTIE) 
is a series of clinical trials where minimally invasive evacuation of ICH and the use of either 
a thrombolytic agent [MISTIE II (2013) and MISTIE III (ongoing)] or a CT-guided endoscope 
(MISTIE-ICES) is under study [15]. Early results were favorable for the successful and early 
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removal of the ICH in addition to demonstrating a fall in the mortality rate and long-term 
qualitative outcome [15].
4.4. Recombinant activated factor VII (rFVIIa) therapy
Recombinant activated factor VII (rFVIIa) therapy, although a well-documented therapy 
in the Haemophilias, it has found limited  application in the indiscriminate use in ICH 
and is associated with multiple thromboembolic complicationsincluding death [11]. It has, 
however, demonstrated a reduction in the growth of the ICH when administered within 
4 h of the ictus. Perihematomal edema and secondary injury are the focus of attention and 
includes altering events at the molecular level, which would precipitate secondary injury 
in ICHs. These include iron-mediated toxicity and acute inflammation which is induced 
by the degradation products of hemoglobin [10]. Multiple modalities, such as the use of 
minocycline, hypothermia and albumin, have been advocated as possible neuroprotective 
agents in the prevention of secondary injury from inflammation in ICH [10]. Deferoxamine 
mesylate is investigated to counter the neurotoxic effects of iron resulting from hemolysis 
of the red blood cells [10]. Preclinical work with Pioglitazone has revealed that the tran-
scription factor peroxisome proliferator-activated receptor gamma plays an essential role 
in enhancing phagocytosis with the dual role of restraining oxidative stress and inflam-
mation [10].
5. Prognosis
There is a slightly more than 1% chance of a survivor of an ICH to endure either a new ICH 
or an ischemic stroke each year [9]. The three most important and reliable indicators of poor 
outcome after ICH are volume of the hematoma, level of consciousness and intraventricular 
hemorrhage (IVH), which is implicated most likely due to the involvement of more centrally 
located structures within the brain [9, 12].
6. Conclusion
Although, hemorrhagic stroke has been known since antiquity, it has been an extremely 
challenging medical condition to treat. One that has been investigated exhaustively, and 
future avenues of treatment will most likely combine several approaches not just at reduc-
ing the size of the hematoma and prevention of its expansion but also therapies aimed at 
mitigating the secondary insult. Further focus, understandably, would rest on grasping 
the molecular mechanisms of the pathogenesis and the innate immune responses and 
formulating remedies to combat these effects. This chapter has attempted a brief over-
view of the topic. Further sections will highlight many aspects of this neurological entity 
in depth, hopefully illuminating our understanding of this ubiquitous but challenging 
disorder.
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